Sie suchten nach: neoadjuverende (Dänisch - Englisch)

neoadjuverende-adjuverende behandling
neoadjuvant-adjuvant treatment

neoadjuverende behandling af brystkræft
neoadjuvant treatment of breast cancer

tidlig brystkræft (neoadjuverende-adjuverende behandling)
early breast cancer (neoadjuvant-adjuvant setting)

studiets primære endepunkt var kardiologisk sikkerhed i studiets neoadjuverende behandlingsperiode.
the primary endpoint of this study was cardiac safety during the neoadjuvant treatment period of the study.

patienterne blev randomiseret til at få én af tre følgende neoadjuverende behandlingsregimer inden operation:
patients were randomised to receive one of three neoadjuvant regimens prior to surgery as follows:

fraværet af lægemiddelinteraktion blev bekræftet af farmakokinetiske data fra neosphere- studiet ved neoadjuverende behandling.
this absence of drug-drug interaction was confirmed by pharmacokinetic data from the neosphere trial in the neoadjuvant setting.

patienterne blev randomiseret til at få 4 serier af ét af følgende neoadjuverende behandlingsregimer inden operation:
patients were randomised to receive one of the following neoadjuvant regimens for 4 cycles prior to surgery:

tidligere adjuverende eller neoadjuverende behandling var tilladt, hvis den var afsluttet mindst 6 uger inden randomisering.
prior adjuvant or neoadjuvant therapy was allowed if it was completed at least 6 weeks prior to randomisation.

i rammerne af neoadjuverende behandling vurderes lokalt avanceret og inflammatorisk brystkræft at indebære høj risiko, uafhængig af hormonreceptorstatus.
in the neoadjuvant setting, locally advanced and inflammatory breast cancers are considered as high- risk irrespective of hormone receptor status.

perjeta skal administreres i kombination med neoadjuverende trastuzumab og kemoterapi i 3 til 6 serier, som led i behandlingsregimet mod tidlig brystkræft.
perjeta should be administered for 3 to 6 cycles in combination with neoadjuvant trastuzumab and chemotherapy, as part of a treatment regimen for early breast cancer.

det er også påvist, at fulvestrant 500 mg nedregulerer er og proliferationsmarkøren ki67 i højere grad end fulvestrant 250 mg ved brysttumorer i et postmenopausalt neoadjuverende regi.
it has also been shown that fulvestrant 500 mg downregulates er and the proliferation marker ki67, to a greater degree than fulvestrant 250 mg in breast tumours in postmenopausal neoadjuvant setting.

kræften har ikke spredt sig til andre dele af kroppen og behandlingen vil blive givet før operation (behandling før operation kaldes neoadjuverende behandling)
the cancer has not spread to other parts of the body and treatment is going to be given before surgery takes place (treatment before surgery is called neoadjuvant therapy)

efter operation, kemoterapi (neoadjuverende eller adjuverende) og strålebehandling (hvis indiceret) (se pkt.
following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1).

hvis patienterne er blevet behandlet samtidigt med et fuldt forløb af lavdosis-antracykliner og herceptin i et neoadjuverende behandlingsregime, bør yderligere cytotoksisk kemoterapi ikke gives efter operation.
if patients have been treated concurrently with a full course of low-dose anthracyclines and herceptin in the neoadjuvant setting, no additional cytotoxic chemotherapy should be given after surgery.

gemcitabin er indiceret til behandling i kombination med paclitaxel af patienter med inoperabel, lokalt tilbagevendende eller metastatisk brystcancer, som har fået tilbagefald efter adjuverende/ neoadjuverende kemoterapi.
gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.

ved neoadjuverende behandling (neosphere-studiet) var incidensen af lvd højere i perjeta- gruppen end hos dem, der ikke fik perjeta.
in the neoadjuvant setting (neosphere) the incidence of lvd was higher in the perjeta–treated groups than in those who did not receive perjeta.

antallet af infusioner afhænger af hvordan du reagerer på behandlingen, og om du får behandling før operation (neoadjuverende behandling) eller behandling for sygdom, som har spredt sig.
the number of infusions you will be given depends on how you respond to treatment and whether you are receiving treatment before surgery (neoadjuvant therapy) or for disease which has spread.

i tabel 1 opsummeres bivirkninger fra det pivotale studie cleopatra, hvor perjeta blev givet i kombination med docetaxel og trastuzumab til patienter med metastatisk brystkræft, samt fra de neoadjuverende studier neosphere og tryphaena, hvor perjeta blev givet i kombination med trastuzumab og kemoterapi til patienter med tidlig brystkræft..
table 1 summarizes the adrs from the pivotal trial cleopatra, in which perjeta was given in combination with docetaxel and trastuzumab to patients with metastatic breast cancer, and from the neoadjuvant trials neosphere and tryphaena, in which perjeta was given in combination with trastuzumab and chemotherapy to patients with early breast cancer.

herceptin er indiceret til behandling af patienter med tidlig her2- positiv brystkræft efter operation, kemoterapi (neoadjuverende eller adjuverende) og stråleterapi (hvis indiceret) (se 5. 1).
herceptin is indicated for the treatment of patients with her2 positive early breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see 5.1).